319 related articles for article (PubMed ID: 7536945)
41. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
42. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
[TBL] [Abstract][Full Text] [Related]
43. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
Uchida H; Kapur S; Mulsant BH; Graff-Guerrero A; Pollock BG; Mamo DC
Am J Geriatr Psychiatry; 2009 Mar; 17(3):255-63. PubMed ID: 19225277
[TBL] [Abstract][Full Text] [Related]
44. D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients.
Regenthal R; Kunstler U; Hesse S; Sabri O; Preiss R
Int J Clin Pharmacol Ther; 2005 Aug; 43(8):370-8. PubMed ID: 16119512
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
[TBL] [Abstract][Full Text] [Related]
46. Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT.
Schlegel S; Schlösser R; Hiemke C; Nickel O; Bockisch A; Hahn K
Psychopharmacology (Berl); 1996 Apr; 124(3):285-7. PubMed ID: 8740053
[TBL] [Abstract][Full Text] [Related]
47. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study.
Meisenzahl EM; Schmitt G; Gründer G; Dresel S; Frodl T; la Fougère C; Scheuerecker J; Schwarz M; Boerner R; Stauss J; Hahn K; Möller HJ
Pharmacopsychiatry; 2008 Sep; 41(5):169-75. PubMed ID: 18763218
[TBL] [Abstract][Full Text] [Related]
48. Dopamine D(2) receptor blockade in schizophrenia.
Bressan RA; Jones HM; Ell PJ; Pilowsky LS
Am J Psychiatry; 2001 Jun; 158(6):971-2. PubMed ID: 11384924
[No Abstract] [Full Text] [Related]
49. Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.
Catafau AM; Corripio I; Pérez V; Martin JC; Schotte A; Carrió I; Alvarez E
Psychiatry Res; 2006 Dec; 148(2-3):175-83. PubMed ID: 17059881
[TBL] [Abstract][Full Text] [Related]
50. Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders.
Breier A; Su TP; Malhotra AK; Elman I; Adler CM; Weisenfeld NI; Pickar D
Neuropsychopharmacology; 1999 Apr; 20(4):340-5. PubMed ID: 10088134
[TBL] [Abstract][Full Text] [Related]
51. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
Tuppurainen H; Kuikka JT; Viinamäki H; Husso M; Tiihonen J
Psychiatry Clin Neurosci; 2009 Aug; 63(4):529-37. PubMed ID: 19496999
[TBL] [Abstract][Full Text] [Related]
52. Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis.
Corripio I; Pérez V; Catafau AM; Mena E; Carrió I; Alvarez E
Neuroimage; 2006 Jan; 29(2):662-6. PubMed ID: 16112587
[TBL] [Abstract][Full Text] [Related]
53. The effects of the atypical antipsychotics clozapine, remoxipride and risperidone on the contractile characteristics of rat skeletal muscle in vitro.
Mendes LS; Collins SP
Pharmacol Res; 1997 Dec; 36(6):457-61. PubMed ID: 9446712
[TBL] [Abstract][Full Text] [Related]
54. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
Meisenzahl EM; Dresel S; Frodl T; Schmitt GJ; Preuss UW; Rossmüller B; Tatsch K; Mager T; Hahn K; Möller HJ
J Psychopharmacol; 2000; 14(4):364-70. PubMed ID: 11198054
[TBL] [Abstract][Full Text] [Related]
55. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors.
He H; Richardson JS
Int Clin Psychopharmacol; 1995 Mar; 10(1):19-30. PubMed ID: 7542676
[TBL] [Abstract][Full Text] [Related]
56. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration.
Chlan-Fourney J; Ashe P; Nylen K; Juorio AV; Li XM
Brain Res; 2002 Nov; 954(1):11-20. PubMed ID: 12393228
[TBL] [Abstract][Full Text] [Related]
57. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.
Nyberg S; Farde L; Eriksson L; Halldin C; Eriksson B
Psychopharmacology (Berl); 1993; 110(3):265-72. PubMed ID: 7530376
[TBL] [Abstract][Full Text] [Related]
58. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W
Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102
[TBL] [Abstract][Full Text] [Related]
59. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study.
Stephenson CM; Bigliani V; Jones HM; Mulligan RS; Acton PD; Visvikis D; Ell PJ; Kerwin RW; Pilowsky LS
Br J Psychiatry; 2000 Nov; 177():408-15. PubMed ID: 11059993
[TBL] [Abstract][Full Text] [Related]
60. Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.
Stone JM; Bressan RA; Erlandsson K; Ell PJ; Pilowsky LS
Psychopharmacology (Berl); 2005 Aug; 180(4):664-9. PubMed ID: 15719226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
